Journal
PUBLIC HEALTH ACTION
Volume 6, Issue 1, Pages 25-31Publisher
INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
DOI: 10.5588/pha.15.0068
Keywords
operational research; SORT IT; MDR-TB; programmatic management
Categories
Funding
- Management Sciences for Health (Arlington, VA, USA)
- United States Agency for International Development (Washington, DC, USA)
- KNCV Tuberculosis Foundation (The Hague, The Netherlands)
- Global Fund (Geneva, Switzerland)
- Bloomberg Philanthropies, New York, NY, USA
- Union
- MSF
- Department for International Development, London, UK
- WHO, Geneva, Switzerland
- Fondation Veuve Emile Metz-Tesch, Luxembourg
- WHO
Ask authors/readers for more resources
Setting: The programmatic management of drug-resistant tuberculosis (TB) in Viet Nam has been rapidly scaled up since 2009. Objectives: To document the annual numbers of patients enrolled for multidrug-resistant tuberculosis (MDR-TB) treatment during 2010-2014 and to determine characteristics and treatment outcomes of patients initiating treatment during 2010-2012. Design: A retrospective cohort study using national reports and data from the national electronic data system for drug-resistant TB. Results: The number of patients enrolled annually for MDR-TB treatment increased from 97 in 2010 to 1522 in 2014. The majority of patients were middle-aged men who had pulmonary disease and had failed a retreatment regimen; 77% had received. 2 courses of TB treatment. Favourable outcomes (cured and treatment completed) were attained in 73% of patients. Unfavourable outcomes included loss to follow-up (12.5%), death (8%) and failure (6.3%). Having had. 2 previous treatment courses and being human immunodeficiency virus-positive were associated with unfavourable outcomes. Conclusion: Increasing numbers of patients are being treated for MDR-TB each year with good treatment outcomes under national programme management in Viet Nam. However, there is a need to increase case detection-currently at 30% of the estimated 5100 MDR-TB cases per year, reduce adverse outcomes and improve monitoring and evaluation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available